Skip to main content
. 2023 Jul 7;202(3):1067–1083. doi: 10.1007/s12011-023-03742-9

Table 4.

Comparison between the three studied groups according to percentage of normal and abnormal tubules

Percentage tubules Control (n = 10) Cisplatin treated (n = 10) PRP treated (n = 10) H p
Normal/total
 Min.–Max. 86.27–98.04 3.45–17.19 56.76–78.33 25.841* <0.001*
 Mean ± SD. 93.34 ± 4.32 8.89 ± 4.88 67.90 ± 9.33
 Median 94.15 7.93 68.61
p1 <0.001* 0.011*
p2 0.011*
Abnormal/total
 Min.–Max. 1.96–13.73 82.81–96.55 21.67–43.24 25.841* <0.001*
 Mean ± SD. 6.66 ± 4.32 91.11 ± 4.88 32.10 ± 9.33
 Median 5.85 92.07 31.39
p1 <0.001* 0.011*
p2 0.011*
Normal/abnormal
 Min.–Max. 628.6–5000.0 3.57–20.75 131.3–361.5 25.841* <0.001*
 Mean ± SD. 2302.5 ± 1685.9 10.05 ± 6.04 237.0 ± 98.25
 Median 1730.0 8.62 232.4
p1 <0.001* 0.011*
p2 0.011*

SD, standard deviation

H, H for Kruskal-Wallis test, pairwise comparison bet. each 2 groups was done using post hoc test (Dunn’s for multiple comparisons test)

p, p value for comparing between the three studied groups

p1, p value for comparing between control and each other group

p2, p value for comparing between cisplatin treated and PRP treated

*Statistically significant at p ≤ 0.05